Available Until 10/20/2025

It’s Genius: Advances in Gene Therapy

Planned in cooperation with the ASHP Emerging Sciences SAG 

ACPE Activity Number: 0204-0000-22-588-H01-P
Release Date: Oct 20, 2022 
Expiration Date: Oct 20, 2025 
Activity Type: Knowledge-based 
CE Credits:  1.0 contact hour, (0.10 CEU)
Activity Fee: Member – Free / Non-Member – Not Available 

This activity is a recording from a live webinar and those that claim credit for the live webinar should not claim credit for this activity.

Activity Overview 

The purpose of this educational session is to describe nomenclature associated with emerging gene therapy development and administration. Place in therapy and clinical evidence for the safety and efficacy for the 2 FDA-approved products will be reviewed and assessed. New therapies in the development pipeline will be discussed. Finally, cost-effectiveness and payment models for gene therapy will be addressed. 


The American Society of Health-System Pharmacists is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

This activity was planned to meet the educational needs of pharmacists who work with patients with specialized disease states that require speciality medications. 

After completing this activity, the learner should be able to… 

1. Discuss approved methods for the delivery of gene therapy treatments. 

2. Describe the complexities of onasemongene abeprvovec-xioi (Zolgensma) and voretigene neparvovec-rzyl (Luxturna) administration to relevant stakeholders. 

3. Identify key concepts pharmacy programs should consider when providing services for patients receiving gene therapy. 

4. Describe  implications of gene therapy on pharmacy practice and the health care industry. 

  • Introduction and Announcements 

  • Presentation  

  • Questions, Answers, and Discussion 

Scott Canfield, PharmD
Assistant Director, Clinical Program Development
John Hopkins Home Care Group
Baltimore, MD

Deanna Moretz, PharmD, BCPS
Oregon State University College of Pharmacy
Portland, OR

In accordance with our accreditor’s Standards of Integrity and Independence in Accredited Continuing Education, ASHP requires that all individuals in control of content disclose all financial relationships with ineligible companies. An individual has a relevant financial relationship if they have had a financial relationship with an ineligible company in any dollar amount in the past 24 months and the educational content that the individual controls is related to the business lines or products of the ineligible company. 

An ineligible company is any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. The presence or absence of relevant financial relationships will be disclosed to the activity audience. 

  • No one in control of the content of this activity has a relevant financial relationship (RFR) with an ineligible company. 

This activity consists of recordings of faculty slides presentations, active learning activities, discussion, and handouts. Participants must participate in the activity in its entirety to claim continuing pharmacy education credit online at ASHP Learning Center. Follow the prompts online to complete the evaluation, claim credit and view the statement of credit immediately after completing the activity. 

Per ACPE requirements, CPE credit must be claimed within 60 days of being earned. Once you have processed and claimed your CE credit, we encourage you to check your NABP eProfile account to verify your credits were transferred successfully before the ACPE 60-day deadline. It is an electronic direct-report process so your credits should appear in your account within a few minutes. After the 60 day deadline, ASHP will no longer be able to report your credit(s) for this activity.